PYXS insider buying and SEC filings, explained
Pyxis Oncology, Inc. · CIK 1782223
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$123K
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 1, 2026 | Other purchase Amended filing | Craig D Gordon (10% owner) bought 12,689,000 shares in 2 share classes indirectly; the filing does not report a price. New position of 7,172,000 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 3 other reporting owners. This amends a filing from Oct 2. | SEC filing Filed Oct 9, 2026, 2:39 PM ET |
| Jun 30, 2026 | Planned (10b5-1) | Jakob Dupont (Director) sold 35,000 shares at about $3.06 ($107K), marked as a 10b5-1 plan trade. Holdings down 47% to 38,741 shares. | SEC filing Filed Jul 2, 2026 |
| Apr 14–21, 2025 | Planned (10b5-1) | Rachel Humphrey (Director) sold 15,496 shares between Apr 14, 2025 and Apr 21, 2025 at about $1.02 ($16K), marked as a 10b5-1 plan trade. Holdings down 16% to 81,309 shares. | SEC filing Filed Mar 25, 2026 |
13 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow PYXS in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.